See the full story in the original article.
Read the original on kdhnews.com ↗
Keywords
Wall StreetNVDAoil pricesartificial intelligence
Open a keyword to see other news on the same topic.
Related tickers and likely impact
QQQ
▼ Likely negativeInvesco QQQ Trust
Relevance: medium
| Market | US stocks |
|---|---|
| Sector | ETF |
| Close on 10/22/2026 | 704.47 |
| Change that session | -2.86% |
NVDA
▼ Likely negativeNvidia
Relevance: low
| Market | US stocks |
|---|---|
| Sector | Information Technology |
| Industry | Semiconductors |
| Market cap | $5.2T |
| Close on 10/22/2026 | 212.21 |
| Change that session | -4.40% |
SPY
▼ Likely negativeSPDR S&P 500 ETF
Relevance: low
| Market | US stocks |
|---|---|
| Sector | ETF |
| Close on 10/22/2026 | 763.96 |
| Change that session | -1.18% |
PVD
▲ Likely positivePetroVietNam
Relevance: low
| Market | Vietnam stocks |
|---|---|
| Exchange | HOSE |
| Sector | Oil & Gas |
| Industry | Oil Equipment & Services |
| Market cap | 17,534 bn VND |
| P/E | 15.8 |
| P/B | 1.01 |
| Close on 10/23/2026 | 18.70 |
| Change that session | -1.06% |
Impact is scored by AI from the headline and may be wrong. It is not investment advice.
Related news
- AI funding fears rattle Wall Street. Here's how we're adjusting our portfolio
Wall Street struggled last week as concerns about financing the AI boom overshadowed strong earnings. Meta reported negative free cash flow for the first time since its 2012 IPO, and CoreWeave fell 10% Thursday as investors scrutinized its borrowing costs, before the Dow dropped more than 1% Friday as oil surged on fears of renewed U.S. strikes against Iran. For the week, the Dow gained 0.4%, the S&P 500 fell 0.5% and the Nasdaq slipped 0.7%. The portfolio bought 10 shares of GE Vernova and upgraded it to a buy-equivalent 1 rating, while reducing broader AI exposure by exiting Broadcom at an average gain of roughly 128% and trimming CrowdStrike, which had a gain of about 187%. Defensive stocks like Kimberly-Clark (up 4.3%) and Home Depot (up 3.3%) benefited, while Meta, down more than 9% for the week, kept a hold-equivalent 2 rating and $800 price target.
- Markets today : Wall Street lower as AI stocks , oil weigh ; ASX set to slide
Wall Street fell as AI stocks slid and oil hit its highest level since May on worries about the war with Iran, with the S&P 500 down 1.3%, the Nasdaq composite down 2.4% and the Dow down 0.1%. Australian futures pointed to a 19-point (0.2%) loss at the open after the ASX lost 0.4% on Thursday. Concerns about the cost of borrowing to build data centres and buy AI chips weighed on the sector: Lam Research fell 11.1% despite profit and revenue beating expectations, after a 52.4% gain so far this year, while Meta lost 7.4% despite stronger-than-expected revenue, and Nvidia fell 4.3% and CoreWeave 9.6%. Brent crude rose 2.9% to $111.99 a barrel, while the 10-year Treasury yield fell to 4.98% from 5.13% as investors sought safer assets.
- Wall Street tumbles as worries about AI trade and high oil prices weigh
- World shares are mixed after Wall Street AI - related losses , while oil prices jump
World stocks were mixed after AI-related sell-offs on Wall Street, while oil prices jumped as efforts to bring the U.S. and Iran back to the negotiating table stalled. S&P 500 futures fell 0.3%, Dow Jones futures slid 0.6% and Nasdaq futures dipped 0.1%. Brent crude rose 1.6% to $114.92 a barrel and U.S. crude gained 1.8% to $101.22, while the U.S. national average for regular gasoline reached $4.29 a gallon. Meta fell 7% and Nvidia 4.4% on Thursday on worries about rising AI investment costs, while Tesla fell 3.1% despite a stronger-than-expected profit, as its revenue was weaker than forecast. In Europe, Germany's DAX fell 0.8%, France's CAC 40 dropped 0.7% and the UK's FTSE 100 declined 0.5%, while most Asian markets rose.
- World shares are mixed after Wall Street AI - related losses , while oil prices jump
World shares were mixed on Friday as oil hovered near its highest level since May on worries about the war with Iran, with Brent crude up 0.8% to $114.02 a barrel. In Europe, Germany's DAX fell 0.4% and France's CAC 40 dropped 0.6% to 7,765.74, while in Asia Hong Kong's Hang Seng rose 0.7% and the Shanghai Composite gained 0.9%. On Thursday the S&P 500 fell 1.2% for its worst day since July as tech stocks slumped, even though most U.S. stocks rose; Meta lost 7%, Nvidia fell 4.4% and CoreWeave dropped 10.1% amid concerns over the cost of borrowing to fund AI. The 10-year Treasury yield fell to 4.97% from 5.13% as investors bought government bonds for safety. The article also says worries about government debt and strained budgets are weighing on almost every developed economy.
- MARKETS LIVE : Wall Street opens lower as AI spending doubts and oil price surge weigh on sentiment
Wall Street opened lower on Thursday as doubts over returns on heavy AI spending, disappointing Tesla and Meta results, and surging oil prices hit sentiment. The Dow fell 67.7 points (0.13%) to 52,788.41, the S&P 500 dropped 62.6 points (0.81%) to 7,694.62, and the Nasdaq Composite lost 394.5 points (1.48%), with the Nasdaq 100 losing about 500 points in the first 13 minutes. Meta fell 6.51% to $652.10, Tesla 1.91% to $379.10 and Nvidia 1.76% to $218.07. Oil prices hit their highest since May, with Brent above $111 a barrel, after the New York Times reported that the US and Israel had drawn up plans for renewed strikes on Iran following the November 3 midterm elections. Spot gold fell 1.46% to $4,071.56 an ounce, while the FTSE 100 edged up 0.01% to 10,754.13.
Related markets
Latest news
- Biotech stocks are surging. How investors can play the new drug innovation boom
Biotech stocks are rallying: the iShares Biotechnology ETF (IBB) is up 24% through October 23, after a 28% gain in 2025, with two dozen of its 233 holdings more than doubling year-to-date. Moderna leads with a 587% surge, though its stock fell 18% after a leak of positive cancer-vaccine trial data. Analysts attribute the rally to clinical trial results, M&A, and technologies such as mRNA, genomics and AI, with about a dozen novel biologics approved by the FDA in 2025 out of 46 approvals and roughly 66 novel drugs in the pipeline. The Moderna–Merck melanoma drug showed a 42% reduction in recurrence or death when combined with Keytruda in Phase 3 and is targeted for FDA submission and launch in 2027. Gene-sequencing firm Illumina more than doubled this year, and 10x Genomics rose more than 300%.
- SpaceX's "Super Intelligence" Segment Just Made the Stock a Must-Own
SpaceX's 'super intelligence' (SI) segment, formerly its AI business, generated $7.56 billion in Q3 revenue, up 830% from $813 million in 2025 and well above $2.56 billion in Q2. Most of the growth came from AI models, including subscription platforms, and infrastructure, which rose from $2.56 billion to $7.02 billion; X ad revenue grew from $454 million to $538 million. The segment's capital expenditures reached $16.4 billion in the quarter. The author views the stock as attractively priced at current levels if growth continues, but argues that such a pace may be hard to sustain, and the stock gave back its roughly 10% post-earnings gain by Thursday.
- Top Blockchains Continue to See Rapid Growth in AI Agent Payments. This Is the 1 Crypto You Need to Buy Right Now.
Chainalysis reported 138.5 million payments on Base using x402, a payment protocol built for AI agents, up from 58,800 transactions as of Q3 2025. Over 87% of x402 transactions were between $0.0001 and $0.10, sizes too small for traditional networks like Visa and Mastercard because of fees and chargeback risk. Solana ranks second in x402 volume, has overtaken Base in daily activity at several points this year, and launched batch settlement, which BlockRunAI says saves more than $20,000 a month in fees. However, TRM Labs counted $52.7 million across 198.9 million settlements since March 2025, with about $25.6 million plausible after removing suspicious activity, so agent payments are not yet driving much economic activity. Solana's stablecoin supply hit a record $17.3 billion in September, and the token trades about 64% below its January 2025 high of $293.
- 5 of the Fastest-Growing Stocks in the Market
The article ranks five fast-growing stocks by latest-quarter revenue growth: Nebius Group (NBIS), CoreWeave (CRWV), AppLovin (APP), Robinhood Markets (HOOD) and IREN (IREN), and examines what investors are paying for that growth. Nebius's second-quarter revenue jumped 454% year over year to $582.3 million, but at a price-to-sales ratio (P/S) of about 46, the highest of the five, its growth is largely funded by cash, customer prepayments and outside financing. CoreWeave's revenue rose 112.5% to around $2.6 billion, backed by a $104 billion revenue backlog, and it trades at 6.0 times sales, but $640 million in net interest expense means its growth relies heavily on debt. AppLovin grew revenue 53% to $1.9 billion, funded by its own profits and cash, at about 16 times sales, while Robinhood's revenue rose 32% to a record $1.3 billion at about 23 times sales, though trading activity can fall sharply when markets cool. IREN's total revenue fell 26.7% to $137.2 million as Bitcoin mining declined, while AI cloud revenue grew tenfold to $70.5 million at about 19 times sales; the article suggests AppLovin could be the safest option because its growth is funded by profits.
- Down Roughly 50% From Its Highs, Is Netflix Stock Finally a Buy?
Netflix (NFLX) shares have fallen roughly 50% from their all-time closing high of $133.91 on June 30, 2025, following the company's third-quarter report. Before the report, Netflix fired its chief content officer and announced its largest layoff since 2022, hiring former Disney executive Peter Rice as it struggled to produce U.S. blockbuster shows. In Q3, revenue rose 12% to $12.87 billion and adjusted EPS jumped 49% to $0.87, above the $0.82 analyst estimate compiled by LSEG. Netflix guided Q4 revenue to $13.4 billion but trimmed full-year revenue to $51.1 billion and cut its ad revenue forecast from $3 billion to $2.7 billion due to a slower ad rollout. The article argues that at a forward P/E of about 17 times 2027 estimates, the valuation now looks attractive.
- Meta Just Unveiled a New Takeover Weapon — But There's a Catch
Meta Platforms plans to create a non-voting Class C share class that it could use to raise capital, pay employees and acquire companies as it spends heavily on AI. Shareholders will receive one Class C share for each Class A and Class B share through a one-time dividend, effective January 19, 2027. According to the SEC filing, the structure preserves CEO Mark Zuckerberg's control: he holds about 60.6% of the vote while owning roughly 13.4% of the company, and he can sell 20% of his new Class C shares right away. The filing flags two drawbacks: Class C shares are expected to trade at a discount to voting stock, which would cause more dilution for existing holders, and they cannot meet the voting-stock requirements for certain tax-deferred deals. Meanwhile, third-quarter capex of $34.91 billion left free cash flow at negative $2.12 billion, and Meta expects 2026 capex of $135 billion to $145 billion.
Get the briefing on Telegram or Zalo
Join the Upside Telegram channel or Zalo group for the Vietnam stocks and gold briefing at 8:00 and 19:00 (Vietnam time) on trading days, plus a weekly wrap on Saturday morning.